Select Your Region
Global
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
- Autoimmune Disorder
- Multiple Sclerosis (MS)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Completed
This study runs in
Cities
- A Coruña
- Aarhus
- Ancona
- Ankara
- Augsburg
- Barcelona
- Barletta
- Basel
- Berg
- Bergamo
- Bergen
- Berlin
- Besançon
- Birmingham
- Bochum
- Bologna
- Bonn
- Bordeaux
- Breda
- Bron
- Bruxelles
- Buchholz in der Nordheide
- Böblingen
- Cagliari
- Castelló de la Plana
- Catania
- Chieti
- Clermont-Ferrand
- Coppito
- Cork
- Cádiz
- Drammen
- Dresden
- Dublin
- Dublin 4
- Düsseldorf
- Edegem
- Edinburgh
- El Palmar
- Erbach
- Exeter
- Firenze
- Frankfurt am Main
- Freiburg im Breisgau
- Gallarate
- Geleen
- Genova
- Gent
- Girona
- Glasgow
- Glostrup
- Göteborg
- Hamburg
- Hannover
- Heidelberg
- Hennigsdorf
- Hlavní město Praha
- Inverness
- İstanbul
- Itzehoe
- İzmir
- Jihlava
- Jihomoravský kraj
- Jönköping
- Kassel
- Kocaeli
- Kogarah
- L'Hospitalet de Llobregat
- La Louvière
- Lausanne
- Lazio
- Leeds
- Leipzig
- Leuven
- Lille
- Lleida
- Lombardy
- London
- Madrid
- Magdeburg
- Mainz
- Marburg
- Marseille
- Mersin
- Milano
- Montichiari
- Montpellier
- München
- Münster
- Nantes
- Naples
- Napoli
- Neuruppin
- Newcastle upon Tyne
- Nice
- Nieuwegein
- Odense
- Oldenburg in Holstein
- Oviedo
- Padova
- Palermo
- Paris
- Pavia
- Pelt
- Perugia
- Potsdam
- Pozuelo de Alarcón
- Pozzilli
- Reims
- Roma
- Rotterdam
- Salford
- Samsun
- San Giovanni Rotondo
- Sevilla
- Sheffield
- sicilia
- Siena
- Steenokkerzeel
- Stockholm
- Strasbourg
- Stuttgart
- Swansea
- Sønderborg
- Tallinn
- Tampere
- Tartu
- Tilburg
- Toulouse
- Tours
- Trabzon
- Truro
- Turku
- Tübingen
- Ulm
- València
- Verona
- Vigo
- Westerstede
Trial Identifier:
NCT02861014 2015-005597-38 MA30005
Study Summary
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.
Hoffmann-La Roche
Sponsor
Phase 3
Phase
NCT02861014, MA30005, 2015-005597-38
Trial Identifier
Ocrelizumab
Treatments
Multiple Sclerosis, Relapsing-Remitting
Condition
Official Title
An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Eligibility Criteria
All
Gender
≥18 Years & ≤ 55 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
- Have a length of disease duration, from first symptom, of less than (<) 10 years
- Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
- Suboptimal disease control while on a DMT
- Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
- For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug
Exclusion Criteria
- Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
- Inability to complete an Magnetic Resonance Imaging (MRI) procedure
- Known presence of other neurological disorders
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- History or currently active primary or secondary immunodeficiency
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- History of opportunistic infections
- History or known presence of recurrent or chronic infection
- History of malignancy
- Congestive heart failure
- Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds
For the latest version of this information please go to www.forpatients.roche.com